Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Lung Neoplasms 7Breast Neoplasms 7Ovarian Neoplasms 5Neoplasm Metastasis 5Endometrial Neoplasms 5Pancreatic Neoplasms 4Fallopian Tube Neoplasms 4Adenocarcinoma Of Esophagus 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Esophageal Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Pancreatic Cystic Neoplasm 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Locally Advanced Cervical Adenocarcinoma 1

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Taxes × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡